Candida Research Today is a free monthly online journal that collates and summarizes the latest research about Candida, including details on thrush infections, yeast, diet, treatment, symptoms.

Catalase activity in Candida albicans exposed to antineoplastic drugs.

Linares CE, Griebeler D, Cargnelutti D, Alves SH, Morsch VM, Schetinger MR

Departamento de Química, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Av. Roraima, 97105-900. Santa Maria, RS, Brazil.

An increased catalase activity in Candida spp. has been suggested as a mechanism that reduces amphotericin B activity. Furthermore, resistance to antifungal agents like amphotericin B has been reported in some cancer patients undergoing chemotherapy treatment. In this study we analysed the influence of chemotherapy agents on catalase activity in Candida albicans, the major species involved in yeast infections. Eight strains of C. albicans isolated from HIV-positive patients were exposed to cyclophosphamide, cytarabine, dacarbazine and methotrexate antineoplastic drugs at the concentrations used during therapy. Catalase activity was measured and compared to the control group. Very significant differences (P < 0.01) were found when C. albicans was exposed to methotrexate (2 microg ml(-1) = 4 microM). For cyclophosphamide (50 microg ml(-1)), cytarabine (1 microg ml(-1)) and dacarbazine (8 microg ml(-1)), no differences were found (P > 0.05) between the control and drug-exposed groups. Although more extensive studies are necessary, these data do suggest that the antineoplastic drug methotrexate contributes to the resistance to antifungal drug therapy by varying catalase activity.

Published 14 February 2006 in J Med Microbiol, 55: 259-62.
Full-text of this article is available online (may require subscription).

© 2004-2008 Candida Research Today. All Rights Reserved.